Shin Nippon Biomedical Laboratories, Ltd. (TYO:2395)

TYO:2395 Revenue

Shin Nippon Biomedical Laboratories had revenue of 7.87B JPY in the quarter ending June 30, 2026, with 21.48% growth. This brings the company's total for the last twelve months to 33.92B, up 1.72% year-over-year. In the fiscal year ending March 31, 2026, Shin Nippon Biomedical Laboratories had annual revenue of 32.52B with 0.34% growth. That makes Shin Nippon Biomedical Laboratories the 16,889th largest company in the world by revenue and 1,846th in Japan.

• Revenue (ttm): 33.92B
• Revenue Growth: +1.72%
• P/S Ratio: 1.81
• Revenue / Employee: 20.19M
• Employees: 1,680
• Market Cap: 61.28B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• CRO Business 31.28B 91.1%
• Other 1.97B 5.7%
• Medipolis Business 804.31M 2.3%
• US Property Management Business 184.40M 0.5%
• Translational Research Business 108.20M 0.3%

By Geography

Chart

• Japan 21.08B 64.8%
• United States of America 8.52B 26.2%
• Korea 1.59B 4.9%
• Others 1.34B 4.1%

Fiscal year ended Mar 31, 2026 See the full TYO:2395 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Mar 31, 2026	32.52B	111.00M	0.34%
Mar 31, 2025	32.41B	5.96B	22.54%
Mar 31, 2024	26.45B	1.36B	5.42%
Mar 31, 2023	25.09B	7.34B	41.37%
Mar 31, 2022	17.75B	2.64B	17.46%

Data Source: S&P Global Market Intelligence Last updated: Aug 5, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 22, 2026

Data Sources Report a data error